Welcome to our dedicated page for Aimfinity Investment I SEC filings (Ticker: AIMWF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Aimfinity Investment I's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Aimfinity Investment I's regulatory disclosures and financial reporting.
Aimfinity Investment Corp. I reported shareholder approval of two charter amendments to keep its SPAC process moving. The extension amendment lets the company extend its business combination deadline by up to nine one‑month periods to July 28, 2026, with a deposit of $500 into the trust account for each extension. The NTA amendment removes the prior requirement to maintain net tangible assets of at least $5,000,001 in connection with redemptions or closing.
To fund the first extension from October 28, 2025 to November 28, 2025, the company issued a $500 unsecured promissory note to the sponsor’s designee, exchangeable at closing of the Docter Inc. business combination into PubCo ordinary shares at $10.00 per share. The extension proposal passed with 2,785,849 votes for, 2,097 against, 4 abstain; the NTA change passed with 2,787,946 for, 0 against, 4 abstain. As of September 29, 2025, shares outstanding were 1,758,476 Class A and 2,012,500 Class B.
Aimfinity Investment Corp. I reported shareholder approval of two charter amendments to keep its SPAC process moving. The extension amendment lets the company extend its business combination deadline by up to nine one‑month periods to July 28, 2026, with a deposit of $500 into the trust account for each extension. The NTA amendment removes the prior requirement to maintain net tangible assets of at least $5,000,001 in connection with redemptions or closing.
To fund the first extension from October 28, 2025 to November 28, 2025, the company issued a $500 unsecured promissory note to the sponsor’s designee, exchangeable at closing of the Docter Inc. business combination into PubCo ordinary shares at $10.00 per share. The extension proposal passed with 2,785,849 votes for, 2,097 against, 4 abstain; the NTA change passed with 2,787,946 for, 0 against, 4 abstain. As of September 29, 2025, shares outstanding were 1,758,476 Class A and 2,012,500 Class B.
Aimfinity Investment Corp. I filed an 8-K to supplement its proxy materials for the Extraordinary Meeting. The company extended the deadline for public shareholders to submit redemption requests or reversals from October 23, 2025, 5:00 p.m. ET to October 27, 2025, 11:00 a.m. ET.
The filing clarifies that holders who previously elected to redeem in connection with the Docter Business Combination must reverse or withdraw that prior request and then submit a new redemption election for this Extraordinary Meeting if they wish to redeem now. It also notes there is no assurance the meeting will be held if the Docter Business Combination is completed beforehand; any proposed closing date will be announced at least 2 business days in advance.
Meeting logistics are unchanged: the session remains on October 27, 2025 at the Taiwan location with virtual access. The record date remains September 29, 2025.
Aimfinity Investment Corp. I filed an 8-K to supplement its proxy materials for the Extraordinary Meeting. The company extended the deadline for public shareholders to submit redemption requests or reversals from October 23, 2025, 5:00 p.m. ET to October 27, 2025, 11:00 a.m. ET.
The filing clarifies that holders who previously elected to redeem in connection with the Docter Business Combination must reverse or withdraw that prior request and then submit a new redemption election for this Extraordinary Meeting if they wish to redeem now. It also notes there is no assurance the meeting will be held if the Docter Business Combination is completed beforehand; any proposed closing date will be announced at least 2 business days in advance.
Meeting logistics are unchanged: the session remains on October 27, 2025 at the Taiwan location with virtual access. The record date remains September 29, 2025.